Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Key Points

• Bayer Aktiengesellschaft experienced a 69.5% decline in short interest from August to September, with a total of 71,500 shares shorted as of September 15th.
• The company's recent quarterly earnings report showed an EPS of $0.35, exceeding analysts' expectations of $0.25, and a revenue of $12.42 billion against an anticipated $10.79 billion.
• Analysts have mixed views on BAYRY stock, with ratings ranging from "hold" to "strong-buy," leading to a consensus rating of "Buy."

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the target of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 71,500 shares, a decline of 69.5% from the August 31st total of 234,600 shares. Based on an average daily volume of 849,700 shares, the short-interest ratio is currently 0.1 days. Based on an average daily volume of 849,700 shares, the short-interest ratio is currently 0.1 days.

Bayer Aktiengesellschaft Trading Up 4.9%

Shares of BAYRY opened at $8.70 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.13 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a 12-month low of $4.79 and a 12-month high of $8.70. The firm has a market capitalization of $34.19 billion, a PE ratio of -8.97, a price-to-earnings-growth ratio of 3.78 and a beta of 0.90. The stock's fifty day simple moving average is $8.06 and its 200-day simple moving average is $7.32.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.35 EPS for the quarter, beating analysts' consensus estimates of $0.25 by $0.10. The business had revenue of $12.42 billion during the quarter, compared to the consensus estimate of $10.79 billion. Bayer Aktiengesellschaft had a positive return on equity of 15.44% and a negative net margin of 7.61%. As a group, research analysts predict that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on BAYRY shares. Hsbc Global Res upgraded Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, June 11th. Zacks Research lowered Bayer Aktiengesellschaft from a "strong-buy" rating to a "hold" rating in a research note on Monday, September 1st. Wall Street Zen raised Bayer Aktiengesellschaft from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. The Goldman Sachs Group raised Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Thursday, June 5th. Finally, Kepler Capital Markets raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Wednesday, June 11th. Two research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft has a consensus rating of "Buy".

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.